Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial.

Retnakaran R, Kramer CK, Choi H, Swaminathan B, Zinman B

Diabetes care23 Sept 2014Cited by 101 (Europe PMC)

PMID25249651DOI10.2337/dc14-0893PepBankPUB-25249651

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with early type 2 diabetes after intensive insulin therapy, baseline-adjusted beta-cell function (ISSI-2) at 48 weeks was higher with liraglutide than with placebo.
In plain wordsIn adults with early type 2 diabetes, beta-cell function was higher after 48 weeks of liraglutide than with placebo.
Peptide
Liraglutide
Outcome
IncreaseBaseline-adjusted ISSI-2 at 48 weeks
Study
n = 51
Comparator
Placebo
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 48 weeksAs given in this study (human).
Measurements
ISSI-2
339.8
liraglutide
ISSI-2
229.3
placebo
Source sentences
Summary
The primary outcome of baseline-adjusted ISSI-2 at 48 weeks was higher in the liraglutide group than in the placebo group (339.8 ± 27.8 vs. 229.3 ± 28.4, P = 0.008).
1 context sentence(design, population, supporting numbers)
Summary · context
This study determined whether liraglutide can preserve β-cell function over 48 weeks in early T2DM following initial elimination of glucotoxicity with IIT.
Report a problemFND-2524965101
02HumanRandomized controlled trialEfficacy outcome
In adults with early type 2 diabetes, baseline-adjusted HbA1c at 48 weeks was numerically lower with liraglutide than with placebo (P = 0.055), a difference not significant at the usual threshold.
In plain wordsIn adults with early type 2 diabetes, HbA1c was a little lower with liraglutide than with placebo at 48 weeks, but not significantly.
Peptide
Liraglutide
Outcome
No significant changeBaseline-adjusted HbA1c at 48 weeks
Study
n = 51
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 48 weeksAs given in this study (human).
Measurements
HbA1c
6.2%
liraglutide
HbA1c
6.6%
placebo
Source sentences
Summary
Baseline-adjusted HbA1c at 48 weeks was lower in the liraglutide group (6.2 ± 0.1% vs. 6.6 ± 0.1%, P = 0.055) (44 ± 1.1 vs. 49 ± 1.1 mmol/mol).
1 context sentence(design, population, supporting numbers)
Summary · context
This study determined whether liraglutide can preserve β-cell function over 48 weeks in early T2DM following initial elimination of glucotoxicity with IIT.
Report a problemFND-2524965102
03HumanRandomized controlled trialSafety outcome
In adults with early type 2 diabetes, the incidence of hypoglycemia did not differ between liraglutide and placebo.
In plain wordsIn adults with early type 2 diabetes, low blood sugar was no more common with liraglutide than with placebo.
Peptide
Liraglutide
Outcome
No significant changeIncidence of hypoglycemia
Study
n = 51
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 48 weeksAs given in this study (human).
Source sentences
Summary
Despite this level of glycemic control, no difference was found in the incidence of hypoglycemia between the liraglutide and placebo groups (P = 0.61).
1 context sentence(design, population, supporting numbers)
Summary · context
This study determined whether liraglutide can preserve β-cell function over 48 weeks in early T2DM following initial elimination of glucotoxicity with IIT.
Report a problemFND-2524965104
04HumanRandomized controlled trialEfficacy outcome
In adults with early type 2 diabetes, the ISSI-2 advantage of liraglutide over placebo was lost two weeks after stopping treatment.
In plain wordsIn adults with early type 2 diabetes, the beta-cell function advantage of liraglutide over placebo was gone two weeks after stopping treatment.
Peptide
Liraglutide
Outcome
No significant changeISSI-2 two weeks after stopping treatment
Study
n = 51
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 48 weeksAs given in this study (human).
Measurements
ISSI-2
191.9
liraglutide
ISSI-2
238.1
placebo
Source sentences
Summary
Two weeks after stopping treatment, however, the beneficial effect on ISSI-2 of liraglutide versus placebo was entirely lost (191.9 ± 24.7 vs. 238.1 ± 25.2, P = 0.20).
1 context sentence(design, population, supporting numbers)
Summary · context
This study determined whether liraglutide can preserve β-cell function over 48 weeks in early T2DM following initial elimination of glucotoxicity with IIT.
Report a problemFND-2524965105
05HumanRandomized controlled trialEfficacy outcome
In adults with early type 2 diabetes on liraglutide, more than 50% of participants had an HbA1c of 6.0% or lower and non-diabetic glucose tolerance at each quarterly assessment.
In plain wordsIn adults with early type 2 diabetes on liraglutide, over half had HbA1c of 6.0% or lower at each quarterly check.
Peptide
Liraglutide
Outcome
Not applicableParticipants with HbA1c at or below 6.0%
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 48 weeksAs given in this study (human).
Measurements
Proportion with HbA1c <=6.0%
> 50%
liraglutide
Source sentences
Summary
At each quarterly assessment, >50% of participants on liraglutide had an HbA1c ≤6.0% (42 mmol/mol) and glucose tolerance in the nondiabetic range.
1 context sentence(design, population, supporting numbers)
Summary · context
This study determined whether liraglutide can preserve β-cell function over 48 weeks in early T2DM following initial elimination of glucotoxicity with IIT.
Report a problemFND-2524965103

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT01270789

LIraglutide and Beta-cell RepAir (LIBRA) Study

Mount Sinai Hospital, Canadan = 63Jan 2011 to May 2014

Type 2 Diabetes

Trial page ClinicalTrials.govUpdated 12 Sept 2014

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.